Value of COX-2 and HER-2 in Judging Condition and Prognosis in Non-Small Cell Lung Cancer Patients

References

1. ↵
   1. Soslow RA,
   2. Dannenbexg AJ,
   3. Rush D, et al.

   COX-2 pressed in human pulmonary, colonic, and mammary turn. Cancer 2000; 89: 2637-2645.

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   1. Hammock L,
   2. Lewis M,
   3. Phillips C, et al.

   Strong HER-2/neu protein overexression by immunohistochemistry often dose not predict oncogene amplification by fluorescence in situ hybridization. Hum pathol 2003; 34: 1043-1405.

   OpenUrlCrossRefPubMedWeb of Science
3. ↵
   1. Ren XD,
   2. Lü YQ,
   3. Ye KH, et al.

   The anti-tumor molecular mechanisms of non-steroid anti-inflammatory drugs. Zhongguo Yaolixue Tongbao 2005; 21: 527-531 (Chinese).

   OpenUrl
4. ↵
   1. Chen FC,
   2. Pan Q,
   3. Zhang YX, et al.

   Roles of cyclooxygenase-2 and caspase-3 expression in pathogenesis of lung carcinoma: an experiment. Zhonghua Yixue Zazhi 2005; 85: 1916-1920 (Chinese).

   OpenUrl
5. ↵
   1. Laga AC,
   2. Zander DS,
   3. Cagle PT.

   Prognostic significance of cyclooxygenase 2 expression in 259 cases of non-small cell lung cancer. Arch Pathol LabMed 2005; 129: 1113-1117.

   OpenUrlPubMedWeb of Science
6. ↵
   1. Hida T,
   2. Yatabe Y,
   3. Achiwa H, et al.

   Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998; 58: 3761-3764.

   OpenUrlAbstract/FREE Full Text
7. ↵
   1. Zhang YX,
   2. Lai BT,
   3. Chen HL, et al.

   Induction of pulmonary precancerous lesions by tobacco-specific NNK in Wistar rats. Zhongguo Feiai Zazhi 2006; 9: 152-156 (Chinese).

   OpenUrl
8. ↵
   1. Varshney D,
   2. Zhou YY,
   3. Geller SA, et al.

   Determination of Her-2 status and chromosome 17 polysomy in breast carcinomas comparing Herceptest and Path Vysion FISH assay. Am J Clin Pathol 2004; 121: 70-72.

   OpenUrlCrossRefPubMed
9. 1. Nakamura H,
   2. Kawasaki N,
   3. Taguohi M, et al.

   Association of HER-2 overexpression with Prognosis in non-small cell lung carcinoma: a meta analysis. Cancer 2005; 103: 1865-18 73.

   OpenUrlCrossRefPubMedWeb of Science
10. 1. Deng ZC,
    2. Ge D,
    3. Zhang DH, et al.

    Expression of HER-2 family in lung cancer. Zhonghua Jiehehehuxi Zazhi 2002; 25: 207-209 (Chinese).

    OpenUrl
11. ↵
    1. Menard S,
    2. Pupa SM,
    3. Campiglio M, et al.

    Biologic and therapeutic role of HER2 in cancer. Oncogene 2003; 22: 6570-6572.

    OpenUrlCrossRefPubMedWeb of Science
12. ↵
    1. Tan D,
    2. Deeb G,
    3. Wang J, et al.

    HER-2/neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization. Diagn Mol Pathol 2003; 12: 201-201.

    OpenUrlCrossRefPubMed
13. 1. Vallhohmer D,
    2. Brabender J,
    3. Yang DY, et al.

    Sex differences in the predictive power of the molecular prognostic factor HER2/neu in patients with non-small-cell lung cancer. Clin Lung Cancer 2006; 7: 332-337.

    OpenUrlPubMed
14. 1. Lal P,
    2. Salazar PA,
    3. Hudis CA, et al.

    HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single 2 institution experience of 279 cases and comparison of dual color and single color scoring. Am J Clin Pathol 2004; 121: 631-635.

    OpenUrlCrossRefPubMed
15. ↵
    1. Zhang J,
    2. Chen LZ,
    3. Lü YL, et al.

    Correlations of differentiation and metastasis with amplification and expression of Her-2/neu oncogene in human lung cancer. Zhongguo Zhongliu Linchuang 1997; 24: 452-455 (Chinese).

    OpenUrl
16. ↵
    1. Richardson CM,
    2. Sharma RA,
    3. Cox G, et al.

    Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer: potential targets for chemoprevention and systemic therapy. Lung Cancer 2003; 39: 1-13.

    OpenUrlCrossRefPubMedWeb of Science
17. 1. Lonardo F,
    2. Dragnev KH,
    3. Freemantle SJ, et al.

    Evidence for the epidermal growth factor receptor as a target for lung cancer prevention. Clin Cancer Res 2002; 8: 54-60.

    OpenUrlAbstract/FREE Full Text
18. ↵
    1. Niki T,
    2. Kohno T,
    3. Iba S, et al.

    Frequent co-localization of COX-2 and laminin-5 gamma2 chain at the invasive front of early2stage lung Adenocarcinomas. Am J Pathol 2002; 160: 1129-1141.

    OpenUrlCrossRefPubMedWeb of Science
19. 1. Brown JR,
    2. DuBois RN.

    COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005; 23: 2840-2855.

    OpenUrlAbstract/FREE Full Text
20. ↵
    1. Andrew J,
    2. Scott M,
    3. Jason R, et al.

    Cyclooxygenase-2 and epidermal growth factor receptor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005; 23: 254-266.

    OpenUrlAbstract/FREE Full Text